| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1608-FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob | 1 | Y | 1 TGR-1202 + Obinutuzumab | 95 | 26 | 0 | 0 | 0 | 0 | 0 | 01/23/2018 | 192 | 71 |
| 2 Lenalidomide + Obinutuzumab | 27 | 3 | 2 | 0 | 0 | 0 | ||||||||
| 3 CHOP + Obinutuzumab | 12 | 1 | 1 | 0 | 0 | 0 | ||||||||
| 4 Bendamustine + Obinutuzumab | 12 | 1 | 0 | 0 | 0 | 0 | ||||||||
| 77 | 5 | 3 | 0 | 0 | 0 | |||||||||
| S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | 1 | Y | 1 CC-486 + R-miniCHOP | 422 | 47 | 21 | 11 | 4 | 1 | 1 | 05/25/2021 | 172 | 70 | |
| 2 R-miniCHOP | 47 | 25 | 11 | 7 | 1 | 0 | ||||||||
| 94 | 46 | 22 | 11 | 2 | 1 | |||||||||
| S2114-NHL, Rel/Ref, CD19 CAR-T +/- Consolidation | 1 | Y | 0 CD19 CAR T-cell Therapy | 396 | 41 | 41 | 22 | 12 | 7 | 1 | 06/12/2023 | 121 | 34 | |
| 41 | 41 | 22 | 12 | 7 | 1 | |||||||||
| 2 | Y | 1 Mosunetuzumab | 2 | 2 | 1 | 0 | 0 | 0 | 06/12/2023 | |||||
| 2 Polatuzumab | 2 | 2 | 2 | 1 | 0 | 0 | ||||||||
| 3 Mosunetuzumab + Polatuzumab | 2 | 2 | 1 | 0 | 0 | 0 | ||||||||
| 4 Observation | 2 | 2 | 2 | 1 | 0 | 0 | ||||||||
| 8 | 8 | 6 | 2 | 0 | 0 | |||||||||
| S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa | 1 | Y | 1 Tazemetostat (Arm 1) Dose Level 1 | 227 | 2 | 2 | 2 | 1 | 1 | 0 | 09/26/2023 | 95 | 33 | |
| 4 Zanubrutinib (Arm 3) Dose Level 1 | 8 | 8 | 7 | 4 | 2 | 0 | ||||||||
| 10 | 10 | 9 | 5 | 3 | 0 | |||||||||
| Yes | A051902-PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P | 1 | E | Total Registrations | 3 | 3 | 2 | 2 | 1 | 0 | 10/14/2023 | 159 | 70 | |
| 3 | 3 | 2 | 2 | 1 | 0 | |||||||||
| A052101-Lymph, Stg I-IV, Cont v Intermittent Zanub | 1 | E | Total Registrations | 3 | 3 | 3 | 2 | 0 | 0 | 01/03/2024 | 74 | 25 | ||
| 3 | 3 | 3 | 2 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 1 | 1 | 1 | 0 | 0 | 0 | 01/03/2024 | |||||
| 1 | 1 | 1 | 0 | 0 | 0 | |||||||||
| AHOD2131-cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy | 1 | E | Total Registrations | 16 | 16 | 12 | 5 | 2 | 0 | 08/15/2023 | 169 | 104 | ||
| 16 | 16 | 12 | 5 | 2 | 0 | |||||||||
| 2 | E | Total Registrations | 12 | 12 | 11 | 4 | 0 | 0 | 08/15/2023 | |||||
| 12 | 12 | 11 | 4 | 0 | 0 | |||||||||
| E4412-HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin | 1 | E | Total Registrations | 20 | 0 | 0 | 0 | 0 | 0 | 04/17/2019 | 93 | 59 | ||
| 20 | 0 | 0 | 0 | 0 | 0 | |||||||||
| EA4151-Lymph, AHCT +/-Ritux, MRD Neg | 0 | E | Total Registrations | 167 | 24 | 15 | 14 | 3 | 1 | 04/03/2018 | 231 | 88 | ||
| 167 | 24 | 15 | 14 | 3 | 1 | |||||||||
| 1 | E | Total Registrations | 125 | 13 | 6 | 5 | 2 | 0 | 04/03/2018 | |||||
| 125 | 13 | 6 | 5 | 2 | 0 | |||||||||
| No | A051701-LYMPH, MYC/BC2 DHL&DEL, R-chemo+/-Venetoclax | 1 | T | Total Registrations | 34 | 0 | 0 | 0 | 0 | 0 | 01/02/2020 | |||
| 34 | 0 | 0 | 0 | 0 | 0 | |||||||||
| ANHL1931-PMBCL, Chemo-Immunotherapy +/- Nivo | 1 | E | Total Registrations | 20 | 11 | 7 | 5 | 1 | 1 | 02/28/2022 | 214 | 104 | ||
| 20 | 11 | 7 | 5 | 1 | 1 | |||||||||
| Study | Registration/Phase | Open Date | # of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|
| S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation | 3 Crossover | 23-Feb-23 | 121 | 34 |